Back to Search Start Over

Crizotinib in ROS1 and MET Deregulated NSCLC—Response

Authors :
Lorenza Landi
Rossella Bruno
Federico Cappuzzo
Gabriella Fontanini
Source :
Clinical Cancer Research. 26:1775-1775
Publication Year :
2020
Publisher :
American Association for Cancer Research (AACR), 2020.

Abstract

We thank the authors for their interest in our study and for their comments. Wiesweg and colleagues correctly reported that the minor allele frequency of both p.T1010I and p.R988C MET variants is close to 1% in the European population, but these mutations were described also as somatic (T1010I

Details

ISSN :
15573265 and 10780432
Volume :
26
Database :
OpenAIRE
Journal :
Clinical Cancer Research
Accession number :
edsair.doi.dedup.....bae76e8f0ba5983bf66be17504937816
Full Text :
https://doi.org/10.1158/1078-0432.ccr-20-0026